The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| XERS | +184.26% | +65.65% | +10.61% | +290% |
| S&P | +16.9% | +95.99% | +14.39% | +56% |
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company. It engages in developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The firm has three commercial products: Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first and only FDA-approved therapy for primary periodic paralysis, and Recorlev for the treatment of endogenous Cushing's syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $71.54M | 48.8% |
| Gross Profit | $56.93M | 51.6% |
| Gross Margin | 79.58% | 1.4% |
| Market Cap | $747.92M | 124.2% |
| Market Cap / Employee | $1.90M | 0.0% |
| Employees | 394 | 4.5% |
| Net Income | -$1.93M | 87.2% |
| EBITDA | $7.65M | 251.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $59.29M | 2.9% |
| Accounts Receivable | $53.05M | 25.0% |
| Inventory | 67.3 | 56.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $251.07M | -5.1% |
| Short Term Debt | $6.16M | 16.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -9.60% | 8.4% |
| Return On Invested Capital | -46.97% | 29.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$0.10M | 99.1% |
| Operating Free Cash Flow | $0.18M | 101.8% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -14.99 | -17.83 | -27.70 | -20.74 | -42.92% |
| Price to Sales | 2.27 | 2.49 | 3.76 | 3.03 | 64.51% |
| Price to Tangible Book Value | -2.78 | -3.31 | -5.42 | -4.72 | 97.06% |
| Enterprise Value to EBITDA | -64.10 | 146.56 | 19759.23 | 123.28 | -217.96% |
| Return on Equity | -324.2% | -617.2% | - | ||
| Total Debt | $270.97M | $271.45M | $268.75M | $257.22M | -4.66% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
